ERBB2 and breast carcinoma: In that analysis, 49 patients with HER2-positive breast cancer received paclitaxel (P) followed by epirubicin, fluorouracil, and cyclophosphamide (FEC) and concurrent trastuzumab (Trastuzumab Group).